Interview with Rick Doblin, Executive Director and Founder of MAPS
In this episode, Rick and James Hallifax discuss MAPS’ work treating PTSD with MDMA, sending the Soviets Psychedelics, and what the future holds.
In this episode, Rick and James Hallifax discuss MAPS’ work treating PTSD with MDMA, sending the Soviets Psychedelics, and what the future holds.
Biggest difference between the two proposed bills: one decriminalizes plant medicine.
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
MindMed (Nasdaq: MNMD, NEO: MMED) today announced that their Flagship Program, Project Lucy, has been given the green light from the FDA. MindMed is set to start a phase 2b Clinical Trial treating Generalized Anxiety Disorder with MM-102.
In response, MindMed’s stock has SKYROCKETED! It is up 39% at the time of writing and it could go higher. The psychedelic stock has been battered over the last 8 months, so it is good to see positive news affecting the price.
MindMed is a company attempting to treat mental health conditions such as Anxiety and Depression with Psychedelic Therapies.
Can psychedelics relieve anxiety and treat mental health? MindMed wants to know!
#MNMDstock# MindMed #Psychedelics
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.